Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | ACP1 | P24666 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL728757 | 0.86 | ALDH1A1 (0.66) | ALDH1A1TSHRCYP3A4SMN1; SMN2MEN1 | |
| SCHEMBL54880 | 0.86 | ALDH1A1 (0.66) | ALDH1A1TSHRCYP3A4SMN1; SMN2MEN1 | |
| SCHEMBL30410721 | 0.85 | CYP3A4 (0.52) | ALDH1A1TSHRCYP3A4SMN1; SMN2MEN1 | |
| SCHEMBL91278 | 0.83 | TP53 (0.55) | ALDH1A1CYP3A4SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2170079 | 0.83 | CYP3A4 (0.50) | ALDH1A1TSHRCYP3A4SMN1; SMN2MEN1 | |
| SCHEMBL15054592 | 0.83 | TP53 (0.55) | ALDH1A1CYP3A4SMN1; SMN2MEN1KMT2A | |
| SCHEMBL362241 | 0.81 | ALDH1A1 (0.56) | ALDH1A1TSHRCYP3A4SMN1; SMN2MEN1 | |
| SCHEMBL16951368 | 0.79 | CYP3A4 (0.46) | ALDH1A1TSHRCYP3A4SMN1; SMN2MEN1 | |
| SCHEMBL7596117 | 0.79 | ALDH1A1 (0.58) | ALDH1A1TSHRCYP3A4SMN1; SMN2MEN1 | |
| SCHEMBL11689544 | 0.79 | ALDH1A1 (0.58) | ALDH1A1TSHRCYP3A4SMN1; SMN2CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562912-B2 | Heterocyclic derivatives and use thereof | C&C RESEARCH LABORATORIES (KR) | 2020-02-18 | — | — | US | disclosed |
| US-10301288-B2 | Kinase inhibitors | TOPIVERT PHARMA LIMITED (GB) | 2019-05-28 | — | — | US | disclosed |
| CN-105283443-B | Hete rocyclic derivatives and application thereof | 株式会社C&C新药研究所 | 2018-08-17 | — | — | CN | disclosed |
| EP-3004057-B1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS STAT 3 INHIBITORS | C&C RES LAB (KR) | 2018-07-25 | — | — | EP | disclosed |
| US-20180086741-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2018-03-29 | — | — | US | disclosed |
| US-9850233-B2 | Kinase inhibitors | RESPIVERT LIMITED (GB) | 2017-12-26 | — | — | US | disclosed |
| US-20170050939-A1 | SMALL MOLECULE INHIBITORS OF G PROTEIN COUPLED RECEPTOR 6 KINASE POLYPEPTIDES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2017-02-23 | — | — | US | disclosed |
| US-20170050939-A1 | SMALL MOLECULE INHIBITORS OF G PROTEIN COUPLED RECEPTOR 6 KINASE POLYPEPTIDES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2017-02-23 | — | — | US | disclosed |
| US-20160318909-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2016-11-03 | — | — | US | disclosed |
| US-20160108056-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C RESEARCH LABORATORIES (KR) | 2016-04-21 | — | — | US | disclosed |
| EP-1532138-B1 | INHIBITORS OF TYROSINE KINASES | NOVARTIS AG (CH) | 2008-11-19 | — | — | EP | disclosed |
| US-20080188451-A1 | INHIBITORS OF TYROSINE KINASES | BREITENSTEIN WERNER | 2008-08-07 | — | — | US | disclosed |
| CN-101045727-A | Inhibitors of tyrosine kinases | NOVARTIS AG (CH) | 2007-10-03 | — | — | CN | disclosed |
| CN-1324022-C | Tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2007-07-04 | — | — | CN | disclosed |
| US-20070093506-A1 | Inhibitors of tyrosine kinases | BREITENSTEIN WERNER | 2007-04-26 | — | — | US | disclosed |
| US-7169791-B2 | Inhibitors of tyrosine kinases | NOVARTIS AG (CH) | 2007-01-30 | — | — | US | disclosed |
| US-20060167015-A1 | 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol1yl)-3-(trifluoromethyl)phenyl]benzamide or an N-oxide or salts; anticarcinogenic agent (leukaemia) | NOVARTIS AG (CH) | 2006-07-27 | — | — | US | disclosed |
| CN-1675195-A | Tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2005-09-28 | — | — | CN | disclosed |
| EP-1532138-A1 | INHIBITORS OF TYROSINE KINASES | Novartis AG (CH) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004005281-A1 | INHIBITORS OF TYROSINE KINASES | NOVARTIS AG (CH) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093506-A1 | Inhibitors of tyrosine kinases | ABL1, BTK, FLT3 | ALDH1A1 3475/4885TSHR 1204/4885CYP3A4 1492/4885 |
| US-20180086741-A1 | KINASE INHIBITORS | SYK, BTK, SRC | ALDH1A1 4104/4885TSHR 1329/4885CYP3A4 3139/4885 |
| US-10301288-B2 | Kinase inhibitors | SYK, BTK, SRC | ALDH1A1 4104/4885TSHR 1329/4885CYP3A4 3139/4885 |
| US-20170050939-A1 | SMALL MOLECULE INHIBITORS OF G PROTEIN COUPLED RECEPTOR 6 KINASE POLYPEPTIDES | GRK6, GRK2, GRK3 | ALDH1A1 4745/4885TSHR 945/4885CYP3A4 4863/4885 |
| US-20160318909-A1 | KINASE INHIBITORS | SYK, LYN, BTK | ALDH1A1 4245/4885TSHR 466/4885CYP3A4 2366/4885 |
| US-20160108056-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | STAT3, JAK2, STAT5A | ALDH1A1 1646/4885TSHR 1536/4885CYP3A4 2899/4885 |
| US-10562912-B2 | Heterocyclic derivatives and use thereof | STAT3, JAK2, STAT5A | ALDH1A1 1646/4885TSHR 1536/4885CYP3A4 2899/4885 |
| US-20080188451-A1 | INHIBITORS OF TYROSINE KINASES | ABL1, BTK, FLT3 | ALDH1A1 3475/4885TSHR 1204/4885CYP3A4 1492/4885 |
| US-20060167015-A1 | 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol1yl)-3-(trifluoromethyl)phenyl]benzamide or an N-oxide or salts; anticarcinogenic agent (leukaemia) | ABL1, CDK2, CDKN1A | ALDH1A1 2503/4885TSHR 2444/4885CYP3A4 1455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.